Concerns about bone loss with GLP-1s come up often, yet the evidence consistently shows either preservation or slight gains in bone density
However, a small study indicates that it can even completely block the airways in rare cases
GLP-1 receptor agonists (e.g., semaglutide, liraglutide): Revolutionized the treatment of type 2 diabetes and obesity
Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) Japan, Medicines and Healthcare products Regulatory Agency (MHRA) UK, National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report, World Health Organization (WHO) Global Health Observatory, International Diabetes Federation (IDF) Diabetes Atlas, American Diabetes Association (ADA) Standards of Care, European Association for the Study of Diabetes (EASD) Guidelines, IQVIA Institute for Human Data Science, Evaluate Pharma, and national health ministry reports from key markets (China NMPA, India CDSCO, Brazil ANVISA)
Am J Cardiovasc Drugs
